Since MTAP is frequently deleted in human cancers due to its chromosomal proximity to CDKN2A, it was also speculated that inhibitors of PRMT5 could be utilized in potential therapy for MTAP/CDKN2A‐deleted tumors (Mavrakis et al., 2016). Here, CDKN2A is linked to cancer.